{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:03:27Z","timestamp":1790485407099,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005001","name":"Ahvaz Jundishapur University of Medical Sciences","doi-asserted-by":"publisher","award":["U-99017"],"award-info":[{"award-number":["U-99017"]}],"id":[{"id":"10.13039\/501100005001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.arcmed.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T13:41:40Z","timestamp":1647265300000},"page":"368-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Ali","family":"Saeedi-Boroujeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohangiz","family":"Nashibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata A.","family":"Ghadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motowo","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokrollah","family":"Salmanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Mahmoudian-Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ghasem","family":"Hanafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaad","family":"Sharhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khodadadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2022.03.002_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237903","article-title":"A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment","volume":"15","author":"Karlsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and Immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","article-title":"In the eye of the COVID-19 cytokine storm","volume":"20","author":"Vaninov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0007","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1111\/bph.15229","article-title":"The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing","volume":"177","author":"Bertocchi","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0008","article-title":"NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity","volume":"24","author":"Amin","year":"2021","journal-title":"Microbes Infect"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0009","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"24432","DOI":"10.1038\/s41598-021-04133-7","article-title":"Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein","volume":"11","author":"Yalcinkaya","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0011","article-title":"Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice","volume":"75","author":"Zeng","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: a review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08923973.2021.1925293","article-title":"Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19","volume":"43","author":"Saeedi-Boroujeni","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0014","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0016","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1080\/03610926.2015.1134575","article-title":"Relative effect sizes for measures of risk","volume":"46","author":"Olivier","year":"2017","journal-title":"Commun. Stat. -Theory Methods"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631233","article-title":"The Immunopathology of COVID-19 and the Cannabis Paradigm","volume":"12","author":"Paland","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0018","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2021.1851195","article-title":"Drug repurposing: new strategies for addressing COVID-19 outbreak","volume":"19","author":"Shende","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0019","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2020-219725","article-title":"Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider","volume":"80","author":"Alunno","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2020.01844","article-title":"Immunomodulatory Drugs in the Management of SARS-CoV-2","volume":"11","author":"Burrage","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies","volume":"61","author":"Zhao","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arcmed.2021.06.006","article-title":"Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial","volume":"53","author":"Farnoosh","year":"2022","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174615","article-title":"The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial","volume":"914","author":"Shohan","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.intimp.2019.05.006","article-title":"NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy","volume":"73","author":"Parsamanesh","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12950-021-00268-6","article-title":"Anti-inflammatory potential of Quercetin in COVID-19 treatment","volume":"18","author":"Saeedi-Boroujeni","year":"2021","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105465","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS): Where will the drugs come from?","volume":"165","author":"Toogood","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/brainsci10121012","article-title":"Post-COVID-19 Fatigue: Potential Contributing Factors","volume":"10","author":"Rudroff","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0028","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s10067-020-05178-1","article-title":"Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis","volume":"39","author":"Kucuk","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0029","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cid\/ciab437","article-title":"Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients: a case series and review of the literature","volume":"74","author":"Masso-Silva","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0031","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jth.15179","article-title":"Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia","volume":"19","author":"Nicolai","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/cells10010151","article-title":"Significance of NETs Formation in COVID-19","volume":"10","author":"Janiuk","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0033","article-title":"Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice","volume":"12","author":"Lien","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0034","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0036","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/jmv.25900","article-title":"High IL-6\/IFN-\u03b3 ratio could be associated with severe disease in COVID-19 patients","volume":"92","author":"Lagunas-Rangel","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0037","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.23812\/20-1-E","article-title":"Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0038","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5455\/aim.2021.29.45-50","article-title":"Predictive Value of C-reactive Protein, Lactate Dehydrogenase, Ferritin and D-dimer Levels in Diagnosing COVID-19 Patients: a Retrospective Study","volume":"29","author":"Kaftan","year":"2021","journal-title":"Acta Inform Med"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0039","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/jmv.26097","article-title":"Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19","volume":"92","author":"Ali","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","article-title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis","volume":"506","author":"Lippi","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ajem.2021.01.006","article-title":"Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis","volume":"42","author":"Simadibrata","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0042","doi-asserted-by":"crossref","first-page":"217","DOI":"10.33963\/KP.15830","article-title":"D-dimer levels predict COVID-19 severity and mortality","volume":"79","author":"Ruetzler","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0043","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-020-01427-8","article-title":"Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia","volume":"21","author":"Wu","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.arcmed.2022.03.002_bib0044","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40560-020-00466-z","article-title":"D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study","volume":"8","author":"Yao","year":"2020","journal-title":"J Intensive Care"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:50:48Z","timestamp":1759261848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440922000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0188440922000248"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.03.002","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}